Qualigen Therapeutics Engages TD2 as Contract Research Organization for Preclinical Development of QN-302GlobeNewsWire • 03/30/22
Qualigen Therapeutics Announces Three Published Abstracts at American Association of Cancer Research ConferenceGlobeNewsWire • 03/22/22
Qualigen Therapeutics Extends Research Agreement with University of Louisville Research Foundation on RAS ProgramGlobeNewsWire • 03/15/22
Data from Qualigen Therapeutics' Lead Program QN-302 Accepted as Three Poster Presentations at AACR 2022 ConferenceGlobeNewsWire • 02/15/22
Qualigen Therapeutics Engages Professor Stephen Neidle as Scientific Advisor in the Development of Lead Program QN-302GlobeNewsWire • 02/01/22
Qualigen Therapeutics Secures Worldwide Rights to G4-Selective Transcription Inhibitors from University College London to Develop as Cancer TherapeuticsGlobeNewsWire • 01/18/22
5 Short Squeeze Candidates To Watch: Biofrontera Rejoins And Tops List, 2 New Names Enter LeaderboardBenzinga • 12/27/21
Qualigen Therapeutics, Inc. Announces Closing of $8.82 Million Registered Direct OfferingGlobeNewsWire • 12/01/21
QUALIGEN THERAPEUTICS, INC. ANNOUNCES $8.82 MILLION COMMON STOCK REGISTERED DIRECT OFFERINGGlobeNewsWire • 11/29/21
Peer-Reviewed Article Confirms That Qualigen's FastPack® is as Accurate in Thyroid Stimulating Hormone Measurement -- and Much Faster -- Than a Leading Laboratory MethodGlobeNewsWire • 10/19/21
Qualigen to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitGlobeNewsWire • 09/15/21